LONDON, Nov. 13, 2017 /PRNewswire/ -- "The US anticoagulation therapy market projected to grow at a CAGR of 8.5%."The US anticoagulation therapy market is projected to reach USD 27.83 billion by 2022 from an estimated USD 18.49 billion in 2017, at a CAGR of 8.5%. The US anticoagulation therapy market is segmented into products (anticoagulation drugs, PT/INR testing devices) and anticoagulation clinics. The growth of the anticoagulation drugs market is primarily driven by the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants (NOACs). On the other hand, the high cost of NOACs and requirement of significant investments in the development of anticoagulation drugs are the major factors restraining the growth of this market. In addition, the growth of the anticoagulation clinics market is primarily driven by the increasing prevalence of cardiovascular diseases & blood disorders, high level of medication adherence associated with clinics, and rising aging population.Download the full report: https://www.reportbuyer.com/product/5191872"The NOACs segment is expected to grow at the highest CAGR during the forecast period."The anticoagulation therapy market for drugs is categorized into NOACs, warfarin (VKA), and other drugs. The NOACs segment is expected to grow at the highest CAGR during the forecast period. Due to the better safety and efficacy of NOACs, as compared to traditional therapies, the adoption of NOACs is higher as compared to traditional drugs. In addition, key market players such as Portola Pharmaceuticals (received the FDA approval for its NOAC—Betrixaban in July 2017) are focusing on the development of NOACs in order to capitalize on the growth opportunities presented by this shift in market dynamics. Consequently, many other companies are also expected to focus on developing more safe and efficient NOACs in the coming years; this will ensure the continued growth of this segment."By type of clinics, the pharmacy-based anticoagulation clinics segment is expected to grow at the highest CAGR during the forecast period."On the basis of clinics type, the US anticoagulation therapy market for clinics market is categorized into hospitals associated clinics, independent clinics, and pharmacy-based clinics. The pharmacy-based clinics segment is expected to grow at the highest CAGR during the forecast period. In the US, the number of pharmacy-based anticoagulation clinics has increased significantly in the last few years. This due is to the fact that better results are achieved when therapy is managed by expert pharmacists rather than care provided by family physicians. Moreover, the cost of therapy provided by pharmacy-based anticoagulation clinics is comparatively lesser than independent and hospital associated anticoagulation clinics which is expected to drive the market for pharmacy-based anticoagulation clinics.Break of primary participants was as mentioned below:• By Company Type – Tier 1–46%, Tier 2–36% and Tier 3–18%• By Designation – C-level–22%, Director Level–45%, Others–33%Market players such as C. H. Boehringer Sohn (Germany), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer (US), Daiichi Sankyo (Japan), and Portola Pharmaceuticals (US) are the major market players in the US anticoagulation therapy market for drugs while Roche (Switzerland), Abbott (US), Siemens (Germany), Alere (US), and CoaguSense (US) are the major market players in the US anticoagulation therapy market for PT/INR home testing devices.Research Coverage:The US anticoagulation therapy market in this report is segmented by products and clinics. It provides detailed information regarding major factors influencing the growth market (drivers, restraints, and industry-specific opportunities). The study tracks and analyzes competitive developments (such as new product developments and R&D activities) and profiles the key players in the US anticoagulation therapy market.Reasons to buy this report:From an insight perspective, this research report has focused on various levels of analysis—market share of NOACs, company profiles, emerging and high-growth segments of the US anticoagulation therapy market; market drivers, restraints, and opportunities. The report provides the latest reimbursement trends for PT/INR testing, revenue structure, business models of anticoagulation clinics and in-depth impact analysis of NOACs on anticoagulation clinics, allowing buyers to identify the high growth product segment and potential customers and suppliers hence driving revenue growth and profitability.The report provides insights on the following pointers:• Market Penetration: Comprehensive information on anticoagulation therapy solutions offered by the top players in the US anticoagulation therapy market• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the US anticoagulation therapy market• Market Diversification: Exhaustive information about new products, recent developments, and investments in the US anticoagulation therapy market• Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the US anticoagulation therapy marketDownload the full report: https://www.reportbuyer.com/product/5191872
About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers https://www.reportbuyer.com
For more information: Sarah Smith
Research Advisor at Reportbuyer.com Email: [email protected]
Tel: +44 208 816 85 48 Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/the-us-anticoagulation-therapy-market-is-projected-to-reach-usd-2783-billion-by-2022-300554895.html
SOURCE ReportBuyer
